Hadar Lev-Tov on Muck Rack

Hadar Lev-Tov

New York
As seen in: Wiley Online Library, MDPI, JAMA (The Journal of the American Medical Association), Science Magazine, Annals of Internal Medicine, HCP Live, American Journal of Managed Care, Journal of The American Academy of Dermatology (JAAD), Dermatology Times, Today’s Wound Clinic
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hadar

Contact Hadar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Exploring Research Needs and Resources in HS Care

|
By Hadar Lev-Tov, Iltefat H. Hamzavi, Martina L. Porter
| consultantlive.com
Evolving the HS Treatment Paradigm, Long-Term Outcomes with IL-17 Inhibition - Episode 13 Published on: , , Panelists discuss how key research gaps include pediatric studies, understanding disease progression to enable early intervention, managing acute flares, addressing cosmetic concerns from scarring and hyperpigmentation, and highlight educational resources available through the HS Foundation, medical conferences, and specialized training programs.
Open in Who Shared View Duplicates (2) Issue with article?

Emerging Therapies in HS

|
By Hadar Lev-Tov, Iltefat H. Hamzavi, Martina L. Porter
| consultantlive.com
Evolving the HS Treatment Paradigm, Long-Term Outcomes with IL-17 Inhibition - Episode 12 Published on: , , Panelists discuss how the pipeline includes promising therapies like sonelokimab (an IL-17A/F nanobody with potential for better tissue penetration), various JAK inhibitors, IL-1α/β inhibitors, OX40 ligand blockers, and B-cell targeted therapies that may address disease heterogeneity and offer hope for patients with treatment-resistant disease.
Open in Who Shared View Duplicates (2) Issue with article?

Monitoring Adverse Effects and Treatment Response of IL-17 Inhibitors in HS

|
By Hadar Lev-Tov, Iltefat H. Hamzavi, Martina L. Porter
| consultantlive.com
Evolving the HS Treatment Paradigm, Long-Term Outcomes with IL-17 Inhibition - Episode 11 Published on: , , Panelists discuss how they monitor patients through early follow-up visits at 1 to 3 months to assess medication access, manage cutaneous adverse effects, check liver function tests, and use educational handouts and pharmacy support to counsel patients on expected benefits vs risks while maintaining treatment adherence.
Open in Who Shared View Duplicates (2) Issue with article?
See all 35 licensed articles (123 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified